VIDAMED TUNA BENIGN PROSTATIC HYPERPLASIA STUDY
This article was originally published in The Gray Sheet
Executive Summary
VIDAMED TUNA BENIGN PROSTATIC HYPERPLASIA STUDY will evaluate the transurethral needle ablation radiofrequency system in 200 men in a blinded, randomized trial that currently is enrolling patients, the firm announced. VidaMed recently secured FDA approval of an investigational device exemption to conduct the study; the IDE approval follows an "encouraging" 15-patient pilot safety trial the company conducted earlier this year at Palo Alto Veterans Administration Hospital and Stanford University.